Although HDAC is a known target for several disease states, including ALS, several HDAC inhibitors currently available have a host of toxic side effects and warrant further investigation to target specific HDACs in specific patient subgroups (Janssen et al., 2010). Here, HDAC9 is linked to amyotrophic lateral sclerosis.